Last update 14 Aug 2025
Reconnect Labs

Reconnect Labs

Private Company|2021|Switzerland|
10-50
|
reconnect-labs.com

Overview

Basic Info

Introduction
Reconnect Labs is a spin-off of the University of Zürich, with the mission to develop innovative, rapid-acting and sustainable therapies for affective disorders (anxiety, depression, trauma, addiction), and neurodegenerative diseases. It is specialized on the development of next generation psychedelic medicines with increased safety, tolerability and efficacy in mental health applications.

Tags

Nervous System Diseases
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
ADRA2(Adrenergic receptors alpha-2)1
5-HT receptor x MAO-A1

Related

2
Drugs associated with Reconnect Labs
Dexmedetomidine Hydrochloride
Target
ADRA2
Mechanism
ADRA2 agonists
Active Org.
BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. [+15]
Originator Org.
Orion OyjOrion Oyj
Active Indication
Bipolar I disorder [+12]
Inactive Indication
Acute Ischemic Stroke [+15]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date17 Dec 1999
Dimethyltryptamine/Telepathine
Target
5-HT receptor x MAO-A
Mechanism
5-HT receptor modulators [+2]
Active Org.
Reconnect LabsReconnect Labs
Originator Org.
Reconnect LabsReconnect Labs
Active Indication-
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Reconnect Labs
NCT06685965
/ Not yet recruitingPhase 2
A Phase-2, Double-Blind, Randomized, Placebo-controlled, Crossover Dose-Finding, Laboratory-based Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances
NCT05979727
/ TerminatedPhase 1
Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects
NCT05829603
/ CompletedPhase 1
Single-blind, Randomized, Two-arm, Dose-response Study of DMT and Harmine in Healthy Subjects
100 Clinical Results associated with Reconnect Labs
Login to view more data
0 Patents (Medical) associated with Reconnect Labs
Login to view more data
100 Deals associated with Reconnect Labs
Login to view more data
100 Translational Medicine associated with Reconnect Labs
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
1
Phase 2
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Dexmedetomidine Hydrochloride
 ( ADRA2 )		Stress Disorders, Post-Traumatic
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free